Elanco Animal Health Incorporated $ELAN Stock Position Lessened by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 2.7% during the first quarter, Holdings Channel.com reports. The firm owned 3,809,888 shares of the company’s stock after selling 104,926 shares during the quarter. Bank of New York Mellon Corp’s holdings in Elanco Animal Health were worth $91,171,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Elanco Animal Health in the 1st quarter valued at about $2,065,000. Goldman Sachs Group Inc. raised its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Empowered Funds LLC raised its position in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after acquiring an additional 295,651 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. TD Cowen boosted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. lifted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average target price of $28.55.

Insider Activity

In other news, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $25.46 on Wednesday. The stock’s fifty day simple moving average is $23.78 and its 200 day simple moving average is $23.93. The stock has a market capitalization of $12.71 billion, a price-to-earnings ratio of -50.91, a PEG ratio of 1.64 and a beta of 1.68. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the prior year, the business posted $0.37 earnings per share. Elanco Animal Health’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.